Cumberland Pharmaceuticals Inc. (CPIX) Spending and interest coverage
- R&D / revenue · 12 months: Value 13.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.10%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -6.18×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 13.99% | Research and development expense / revenue. Period ending 2026-06-30. $5.58M ÷ $39.90M × 100 ≈ 13.99% |
| Stock-based compensation / revenue · 12 months | 1.10% | Share-based compensation / revenue. Period ending 2026-06-30. $438.13K ÷ $39.90M × 100 ≈ 1.10% |
| Interest coverage · 12 months | -6.18× | Operating income ÷ reported interest expense. $-3.04M ÷ $491.92K ≈ -6.18× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 5.58M USD | Research and Development Expense |
| Revenue | 39.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 438.13K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -3.04M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 491.92K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.58M | $39.90M | $438.13K | $-3.04M | $491.92K | 13.99% | 1.10% | -6.18× | Reported |
| 2026-03-31 | $5.73M | $41.94M | $440.95K | $-7.21M | $418.03K | 13.66% | 1.05% | -17.26× | Reported |
| 2025-12-31 | $5.57M | $44.52M | $408.32K | $-2.79M | $495.99K | 12.50% | 0.92% | -5.63× | Reported |
| 2025-09-30 | $5.31M | $41.28M | $310.97K | $-3.26M | $606.31K | 12.86% | 0.75% | -5.38× | Reported |
| 2025-06-30 | $5.36M | $42.07M | $306.08K | $-2.99M | $633.98K | 12.75% | 0.73% | -4.72× | Reported |
| 2025-03-31 | $4.95M | $41.08M | $297.35K | $-3.27M | $650.78K | 12.06% | 0.72% | -5.03× | Reported |
| 2024-12-31 | $4.82M | $37.87M | $301.89K | $-6.43M | $605.51K | 12.72% | 0.80% | -10.62× | Reported |
| 2024-09-30 | $4.79M | $36.79M | $320.98K | $-10.77M | $561.04K | 13.02% | 0.87% | -19.20× | Reported |
| 2024-06-30 | $5.41M | $37.79M | $327.72K | $-10.94M | $533.75K | 14.31% | 0.87% | -20.50× | Reported |
| 2024-03-31 | $5.49M | $38.83M | $353.64K | $-9.89M | $600.03K | 14.15% | 0.91% | -16.49× | Reported |
| 2023-12-31 | $5.83M | $39.55M | $365.04K | $-9.55M | $667.86K | 14.75% | 0.92% | -14.31× | Reported |
| 2023-09-30 | $5.98M | $37.99M | $398.05K | $-5.65M | $668.52K | 15.73% | 1.05% | -8.46× | Reported |
| 2023-06-30 | $5.76M | $39.32M | $503.39K | $-4.08M | $707.78K | 14.66% | 1.28% | -5.76× | Reported |
| 2023-03-31 | $6.44M | $38.73M | $377.76K | $-5.94M | $652.77K | 16.64% | 0.98% | -9.11× | Reported |
| 2022-12-31 | $6.69M | $40.68M | $447.50K | $-5.70M | $586.00K | 16.44% | 1.10% | -9.74× | Reported |
| 2022-09-30 | $6.90M | $40.27M | $545.38K | $-7.78M | $434.27K | 17.13% | 1.35% | -17.92× | Reported |
| 2022-06-30 | $6.64M | $36.93M | $519.10K | $-9.06M | $304.95K | 17.97% | 1.41% | -29.70× | Reported |
| 2022-03-31 | $6.17M | $35.68M | $738.81K | $-8.65M | $193.19K | 17.30% | 2.07% | -44.75× | Reported |
| 2021-12-31 | $5.68M | $35.05M | $741.87K | $-7.68M | $98.03K | 16.22% | 2.12% | -78.32× | Reported |
| 2021-09-30 | $5.47M | $36.33M | $758.26K | $-5.07M | $106.19K | 15.06% | 2.09% | -47.74× | Reported |
| 2021-06-30 | $5.25M | $37.50M | $858.51K | $-4.71M | $161.38K | 13.99% | 2.29% | -29.21× | Reported |
| 2021-03-31 | $5.31M | $38.05M | $944.90K | $-4.86M | $254.98K | 13.95% | 2.48% | -19.06× | Reported |
| 2020-12-31 | $5.77M | $35.84M | $1.05M | $-6.38M | $263.63K | 16.11% | 2.92% | -24.21× | Reported |
| 2020-09-30 | $6.06M | $47.65M | $1.18M | $-2.36M | $256.93K | 12.73% | 2.48% | -9.20× | Reported |
| 2020-06-30 | $6.51M | $45.33M | $1.27M | $-4.35M | $246.59K | 14.35% | 2.80% | -17.65× | Reported |
| 2020-03-31 | $6.80M | $45.15M | $1.39M | $-4.15M | $218.34K | 15.06% | 3.07% | -18.98× | Reported |
| 2019-12-31 | $6.48M | $45.55M | $1.49M | $-3.62M | $246.19K | 14.22% | 3.26% | -14.72× | Reported |
| 2019-09-30 | $6.69M | $46.81M | $1.47M | $-4.89M | $353.32K | 14.30% | 3.13% | -13.84× | Reported |
| 2019-06-30 | $6.72M | $44.93M | $1.46M | $-4.85M | $307.64K | 14.96% | 3.25% | -15.76× | Reported |
| 2019-03-31 | $6.71M | $43.52M | $1.39M | $-5.12M | $238.46K | 15.43% | 3.19% | -21.45× | Reported |
| 2018-12-31 | $7.32M | $40.20M | $1.36M | $-7.39M | $195.85K | 18.21% | 3.39% | -37.74× | Reported |
| 2018-09-30 | $5.61M | (m) | $1.27M | $-6.03M | $81.78K | (m) | (m) | -73.75× | Reported |
| 2018-06-30 | $5.25M | (m) | $1.23M | $-5.06M | $71.48K | (m) | (m) | -70.84× | Reported |
| 2018-03-31 | $4.88M | (m) | $1.20M | $-5.88M | $79.49K | (m) | (m) | -73.92× | Reported |
| 2017-12-31 | $3.90M | (m) | $1.12M | $-4.08M | $92.90K | (m) | (m) | -43.93× | Reported |
| 2017-09-30 | $4.08M | (m) | $1.08M | $-4.14M | $99.26K | (m) | (m) | -41.66× | Reported |
| 2017-06-30 | $3.78M | (m) | $995.13K | $-3.17M | $119.45K | (m) | (m) | -26.50× | Reported |
| 2017-03-31 | $3.38M | (m) | $931.91K | $-1.59M | $117.67K | (m) | (m) | -13.52× | Reported |
| 2016-12-31 | $3.19M | (m) | $852.10K | $-1.43M | $106.39K | (m) | (m) | -13.47× | Reported |
| 2016-09-30 | $2.43M | (m) | $819.36K | $-313.08K | $97.78K | (m) | (m) | -3.20× | Reported |
| 2016-06-30 | $2.55M | (m) | $481.13K | $-172.33K | $88.51K | (m) | (m) | -1.95× | Reported |
| 2016-03-31 | $2.70M | (m) | $550.81K | $606.91K | $78.75K | (m) | (m) | 7.71× | Reported |
| 2015-12-31 | $3.85M | (m) | $622.50K | $1.11M | $73.86K | (m) | (m) | 15.05× | Reported |
| 2015-09-30 | $4.21M | (m) | $646.20K | $1.90M | $69.57K | (m) | (m) | 27.24× | Reported |
| 2015-06-30 | $4.39M | (m) | $985.92K | $2.61M | $76.63K | (m) | (m) | 34.10× | Reported |
| 2015-03-31 | $4.42M | (m) | $882.38K | $3.15M | $70.42K | (m) | (m) | 44.80× | Reported |
| 2014-12-31 | $3.39M | (m) | $761.66K | $3.56M | $67.07K | (m) | (m) | 53.06× | Reported |
| 2014-09-30 | $3.96M | $35.73M | $736.27K | $140.62K | $92.06K | 11.09% | 2.06% | 1.53× | Reported |
| 2014-06-30 | $4.47M | $32.53M | $695.10K | $-2.36M | $89.47K | 13.73% | 2.14% | -26.41× | Reported |
| 2014-03-31 | $4.99M | $29.86M | $672.09K | $-4.72M | $97.89K | 16.72% | 2.25% | -48.21× | Reported |
| 2013-12-31 | $5.62M | $32.03M | $674.96K | $-3.80M | $103.42K | 17.53% | 2.11% | -36.76× | Reported |
| 2013-09-30 | $4.72M | $37.56M | $560.63K | $1.92M | $78.34K | 12.56% | 1.49% | 24.56× | Reported |
| 2013-06-30 | $4.97M | $43.57M | $550.94K | $6.42M | $71.27K | 11.42% | 1.26% | 90.04× | Reported |
| 2013-03-31 | $5.14M | $48.85M | $550.77K | $9.50M | $67.29K | 10.52% | 1.13% | 141.15× | Reported |
| 2012-12-31 | $5.10M | $48.85M | $636.53K | $8.82M | $71.98K | 10.43% | 1.30% | 122.50× | Reported |
| 2012-09-30 | $6.41M | $48.19M | (m) | $7.28M | $80.83K | 13.31% | (m) | 90.02× | Reported |
| 2012-06-30 | $5.95M | $48.71M | (m) | $7.40M | $97.00K | 12.21% | (m) | 76.25× | Reported |
| 2012-03-31 | $5.42M | $50.73M | (m) | $9.09M | $159.88K | 10.69% | (m) | 56.84× | Reported |
| 2011-12-31 | $5.03M | $51.14M | (m) | $9.85M | $353.50K | 9.83% | (m) | 27.86× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $4.33M | $45.88M | (m) | $6.50M | $1.42M | 9.43% | (m) | 4.57× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $4.99M | $43.54M | (m) | $5.78M | $772.93K | 11.47% | (m) | 7.47× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |